| Literature DB >> 29728881 |
Komal Rizwan1,2, Muhammad Zubair3, Nasir Rasool4, Tariq Mahmood5, Khurshid Ayub5, Noorjahan Banu Alitheen6, Muhammad Nazirul Mubin Aziz7, Muhammad Nadeem Akhtar8, Faiz-Ul-Hassan Nasim9, Snober Mona Bukhary9, Viqar Uddin Ahmad10, Mubeen Rani10.
Abstract
Thiophene derivatives have shown versatile pharmacological activities. The Suzuki reaction proved a convenient method for C-C bond formations in organic molecules. In the present research work novel derivatives of 2,5-dibromo-3-methylthiophene (3a-k and 3l-p) has been synthesized, via Suzuki coupling reaction in low to moderate yields. A wide range of functional groups were well tolerated in reaction. Density functional theory investigations on all synthesized derivatives (3a-3p) were performed in order to explore the structural properties. The pharmaceutical potential of synthesized compounds was investigated through various bioassays (antioxidant, antibacterial, antiurease activities). The compounds 3l, 3g, 3j, showed excellent antioxidant activity (86.0, 82.0, 81.3%), respectively by scavenging DPPH. Synthesized compounds showed promising antibacterial activity against tested strains. 3b, 3k, 3a, 3d and 3j showed potential antiurease activity with 67.7, 64.2, 58.8, 54.7 and 52.1% inhibition at 50 µg/ml. Results indicated that synthesized molecules could be a potential source of pharmaceutical agents.Entities:
Keywords: Antibacterial; Antioxidant; Density functional theory; Palladium; Thiophene
Year: 2018 PMID: 29728881 PMCID: PMC5935605 DOI: 10.1186/s13065-018-0404-7
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Scheme 1Synthesis of 2-bromo-3-methyl-5-arylthiophenes (3a–k) and 2,5-diaryl-3-methyl thiophenes (3l–p). Conditions: (i) 1 (128 mg, 0.5 mmol, 1 eq), 2 (0.55 mmol, 1.1 eq), Pd(PPh3)4 (14.5 mg, 2.5 mol%), K3PO4 (212 mg, 1.0 mmol, 2 eq), 1,4-dioxane (2.5 ml), H2O (0.625 ml), 12 h, 90 °C under argon. (ii) 1 (128 mg, 0.5 mmol, 1 eq), 2 (1.25 mmol, 2.5 eq,), Pd(PPh3)4 (34.6 mg, 6 mol%), K3PO4 (424 mg, 2.0 mmol, 4 eq), 1,4-dioxane (2.5 ml), H2O (0.625 ml), 12 h, 90 °C under argon
Substrate scope of Suzuki cross coupling reaction of 2,5-dibromo-3-methyl thiophene with variety of arylboronic acids
Fig. 1HOMO/LUMO surfaces of compounds (3a)
HOMO and LUMO energies, along with band gap
| Compounds no | EHOMO (eV) | ELUMO (eV) | ΔE (eV) |
|---|---|---|---|
|
| − 5.93 | − 1.39 | 4.54 |
|
| − 5.39 | − 0.92 | 4.47 |
|
| − 5.83 | − 1.38 | 4.45 |
|
| − 5.99 | − 1.50 | 4.49 |
|
| − 5.84 | − 1.69 | 4.15 |
|
| − 5.39 | − 1.12 | 4.26 |
|
| − 6.08 | − 1.77 | 4.31 |
|
| − 5.60 | − 1.06 | 4.52 |
|
| − 5.60 | − 1.05 | 4.55 |
|
| − 6.04 | − 1.43 | 4.61 |
|
| − 5.91 | − 1.40 | 4.50 |
|
| − 5.81 | − 1.59 | 4.21 |
|
| − 4.98 | − 0.86 | 4.12 |
|
| − 5.06 | − 1.16 | 3.89 |
|
| − 5.24 | − 1.04 | 4.19 |
|
| 6.05 | − 1.38 | 4.67 |
Fig. 2ESP maps of compounds 3a–3p, calculated at DFT/B3LYP/6-31G(d,p) level
Antioxidant potential of compounds (3a–k and 3l–p) by DPPH radical scavenging activity
| Entry | Compounds no | Percentage inhibition at 50 µg/ml |
|---|---|---|
| 1 |
| 33.4 ± 0.29 |
| 2 |
| 23.9 ± 0.31 |
| 3 |
| 37.5 ± 0.42 |
| 4 |
| 48.2 ± 0.42 |
| 5 |
| 38.5 ± 0.42 |
| 6 |
| 39.2 ± 0.42 |
| 7 |
| 82.0 ± 0.78 |
| 8 |
| *** |
| 9 |
| 28.9 ± 0.45 |
| 10 |
| 81.3 ± 0.72 |
| 11 |
| 21.9 ± 0.32 |
| 12 |
| 86.0 ± 0.73 |
| 13 |
| 1.19 ± 0.02 |
| 14 |
| 40.9 ± 0.21 |
| 15 |
| 15.1 ± 0.21 |
| 16 |
| 30.9 ± 0.29 |
| 17 | Ascorbic acid | 100 ± 0.99 |
*** Showed no activity. The results are average ± SD of triplicate experiments p < 0.05
Antibacterial activity of synthesized compounds (3a–k and 3l–p) against Gram positive and Gram negative bacteria
| Entry | Product no | % inhibition (50 μg/ml) | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| 1 |
| 67.3 ± 0.76 | *** | 94.5 ± 0.09 | 33.9 ± 0.37 | 27.6 ± 0.08 |
| 2 |
| 39.2 ± 0.45 | *** | 50.1 ± 0.29 | 9.57 ± 0.15 | 5.58 ± 0.05 |
| 3 |
| *** | *** | *** | *** | *** |
| 4 |
| 34.9 ± 0.27 | *** | 7.8 ± 0.09 | *** | 8.34 ± 0.23 |
| 5 |
| *** | *** | *** | *** | ** |
| 6 |
| *** | *** | *** | *** | *** |
| 7 |
| *** | *** | *** | *** | *** |
| 8 |
| 37.6 ± 0.26 | *** | 50.4 ± 0.45 | *** | 12.0 ± 0.02 |
| 9 |
| 41.1 ± 0.47 | *** | 70.4 ± 0.78 | *** | 2.59 ± 0.01 |
| 10 |
| *** | *** | *** | *** | *** |
| 11 |
| 50.5 ± 0.58 | *** | 72.5 ± 0.87 | 20.1 ± 0.06 | 17.3 ± 0.05 |
| 12 | *** | *** | *** | *** | *** | |
| 13 |
| *** | *** | *** | *** | *** |
| 14 |
| 20.8 ± 0.17 | *** | 30.6 ± 0.26 | *** | * |
| 15 |
| *** | *** | *** | *** | *** |
| 16 |
| *** | *** | *** | *** | *** |
| 17 | Control | 100 ± 1.28 | 100 ± 1.21 | 100 ± 1.01 | 100 ± 0.99 | 100 ± 0.99 |
*** Showed no activity. The results are average ± SD of triplicate experiments p < 0.05. Streptomycin was used as control standard drug
Antiurease activity of synthesized compounds (3a–k and 3l–p)
| Entry | Compound no | Percentage inhibition at 50 µg/ml |
|---|---|---|
| 1 |
| 58.8 ± 0.58 |
| 2 |
| 67.7 ± 0.77 |
| 3 |
| 48.9 ± 0.65 |
| 4 |
| 54.7 ± 0.67 |
| 5 |
| 42.9 ± 0.45 |
| 6 |
| 40.3 ± 0.40 |
| 7 |
| 34.2 ± 0.38 |
| 8 |
| 38.8 ± 0.45 |
| 9 |
| 36.9 ± 0.45 |
| 10 |
| 52.1 ± 0.78 |
| 11 |
| 64.2 ± 0.87 |
| 12 | Thiourea | 95.6 ± 0.87 |
The results are average ± SD of triplicate experiments p < 0.05. Thiourea used as positive control